Merck & Company with ticker code (MRK) now have 22 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 125 and 85 calculating the average target price we see 100.14. Now with the previous closing price of 87.15 this now indicates there is a potential upside of 14.9%. The 50 day moving average now sits at 90.71 and the 200 moving average now moves to 84.09. The market capitalisation for the company is $220,877m. Company Website: https://www.merck.com
The potential market cap would be $253,799m based on the market concensus.
Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences to jointly develop and commercialize long-acting treatments in HIV. Merck & Co. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
